CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Lonsurf trifluridine and tipiracil Metastatic colorectal cancer Reimburse with clinical criteria and/or conditions Active
Eylea HD aflibercept 8mg/0.07mL macular degeneration, age related Active
Uplizna inebilizumab Neuromyelitis optica spectrum disorders (NMOSD) Reimburse with clinical criteria and/or conditions Active
Eylea HD aflibercept 8mg/0.07mL diabetic macular edema Active
Crysvita burosumab Treatment of X-Linked Hypophosphatemia Active
N/A Nab-paclitaxel Solid tumours Active
Velsipity etrasimod Ulcerative colitis Active
N/A everolimus Tuberous Sclerosis Complex (TSC) Active
N/A mepolizumab Eosinophilic Granulomatosis with Polyangiitis Active
N/A Nab-paclitaxel Gastrointestinal cancer Active
Last Updated : May 2, 2024